Anti-obesity effects of Laminaria japonica fucoidan in high-fat diet-fed mice vary with the gut microbiota structure

Previous studies have indicated that fucoidan could resist high-fat-diet (HFD)-induced obesity by modulating the composition of gut microbiota. However, the outcome of dietary intervention may differ between individuals due to large inter-individual variability in gut microbiota. Thus, the present study aimed to investigate the possible discrepancy of the anti-obesity effects of fucoidan supplementation in HFD-fed mice models with different gut microbiota communities. In the present study, the anti-obesity effects of fucoidan isolated from Laminaria japonica (FucLⱼ) on normal mice and microbiota-altered mice treated with penicillin or metronidazole were compared and investigated. The 16S rRNA sequencing revealed the differences of gut microbiota among penicillin-treated, metronidazole-treated and normal groups, and mice treated with penicillin were characterized by greater relative abundance of the phylum Bacteroidetes and the families Muribaculaceae and Bacteroidaceae. Furthermore, FucLⱼ ameliorated HFD-induced body weight gain, fat accumulation, serum lipid profiles, insulin resistance, hepatic steatosis and adipocyte hypertrophy in penicillin-treated and untreated mice, while no effects were observed in metronidazole-treated mice. Overall, mice with different initial gut microbiota responded differently to FucLⱼ supplementation on a high-fat diet, and metronidazole-sensitive gut bacteria negatively correlated with obesity symptoms and were required for the anti-obesity effects of FucLⱼ. Moreover, the anti-obesity effects were not dependent on the utilization of FucLⱼ by gut microbiota to produce SCFAs. These findings indicate that evaluation of the gut microbiota structure before dietary interventions is helpful for enhancing the beneficial outcomes of dietary fiber supplementation and provide a rationale for the further application of dietary fucoidan in a personalized way.